SENORES PHARMACEUTICALS L
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, ne… Read more
SENORES PHARMACEUTICALS L (SENORES) - Net Assets
Latest net assets as of September 2025: ₹8.34 Billion INR
Based on the latest financial reports, SENORES PHARMACEUTICALS L (SENORES) has net assets worth ₹8.34 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹12.88 Billion) and total liabilities (₹4.54 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹8.34 Billion |
| % of Total Assets | 64.78% |
| Annual Growth Rate | -36.21% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 215.46 |
SENORES PHARMACEUTICALS L - Net Assets Trend (2022–2025)
This chart illustrates how SENORES PHARMACEUTICALS L's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SENORES PHARMACEUTICALS L (2022–2025)
The table below shows the annual net assets of SENORES PHARMACEUTICALS L from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹94.96 Million | -95.90% |
| 2024-03-31 | ₹2.32 Billion | +409.26% |
| 2023-03-31 | ₹454.99 Million | +24.35% |
| 2022-03-31 | ₹365.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SENORES PHARMACEUTICALS L's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5251.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹899.10 Million | 11.44% |
| Common Stock | ₹460.50 Million | 5.86% |
| Other Components | ₹6.50 Billion | 82.71% |
| Total Equity | ₹7.86 Billion | 100.00% |
SENORES PHARMACEUTICALS L Competitors by Market Cap
The table below lists competitors of SENORES PHARMACEUTICALS L ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Duksan Hi Metal Co.Ltd
KQ:077360
|
$159.57 Million |
|
Zeng Hsing Industrial Co Ltd
TW:1558
|
$159.60 Million |
|
Inmobiliaria del Sur SA
MC:ISUR
|
$159.62 Million |
|
Emro Inc.
KQ:058970
|
$159.67 Million |
|
Flexsteel Industries Inc
NASDAQ:FLXS
|
$159.33 Million |
|
Guangdong Greenway Technology Co Ltd
SHG:688345
|
$159.29 Million |
|
AUPU Home Style Corp Ltd
SHG:603551
|
$159.28 Million |
|
Aeluma, Inc
NASDAQ:ALMU
|
$159.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SENORES PHARMACEUTICALS L's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,042,680,000 to 7,861,900,000, a change of 5,819,220,000 (284.9%).
- Net income of 6,846,015 contributed positively to equity growth.
- New share issuances of 4,717,600,000 increased equity.
- Other factors increased equity by 1,094,773,985.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹6.85 Million | +0.09% |
| Share Issuances | ₹4.72 Billion | +60.01% |
| Other Changes | ₹1.09 Billion | +13.93% |
| Total Change | ₹- | 284.88% |
Book Value vs Market Value Analysis
This analysis compares SENORES PHARMACEUTICALS L's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 94.74x to 3.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | ₹7.95 | ₹752.75 | x |
| 2023-03-31 | ₹9.88 | ₹752.75 | x |
| 2024-03-31 | ₹44.35 | ₹752.75 | x |
| 2025-03-31 | ₹216.18 | ₹752.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SENORES PHARMACEUTICALS L utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.18%
- • Asset Turnover: 26.28x
- • Equity Multiplier: 0.02x
- Recent ROE (0.09%) is below the historical average (9.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 2.71% | 7.04% | 0.24x | 1.62x | ₹-26.68 Million |
| 2023 | 18.53% | 23.87% | 0.27x | 2.88x | ₹38.83 Million |
| 2024 | 15.40% | 14.66% | 0.34x | 3.04x | ₹110.23 Million |
| 2025 | 0.09% | 0.18% | 26.28x | 0.02x | ₹-779.34 Million |
Industry Comparison
This section compares SENORES PHARMACEUTICALS L's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $6,545,015,470
- Average return on equity (ROE) among peers: 25.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SENORES PHARMACEUTICALS L (SENORES) | ₹8.34 Billion | 2.71% | 0.54x | $159.44 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $16.96 Billion | 22.18% | 0.80x | $1.16 Billion |
| Kopran Limited (KOPRAN) | $1.09 Billion | 9.86% | 1.43x | $31.83 Million |
| Marksans Pharma Limited (MARKSANS) | $9.05 Billion | 26.35% | 0.36x | $405.73 Million |
| NGL Fine-Chem Limited (NGLFINE) | $160.59 Million | 15.04% | 1.05x | $40.08 Million |
| Pfizer Limited (PFIZER) | $9.01 Billion | 33.25% | 0.22x | $823.98 Million |
| Sanofi India Limited (SANOFI) | $17.36 Billion | 17.53% | 0.46x | $361.36 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.08 Billion | 79.43% | 0.66x | $319.07 Million |
| SMS Pharmaceuticals Limited (SMSPHARMA) | $2.22 Billion | 9.19% | 1.30x | $97.10 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $982.22 Million | 14.46% | 1.13x | $30.49 Million |